A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration
Sponsor
University of California, San Francisco (Other)
Overall Status
Completed
CT.gov ID
NCT00187525
Collaborator
Forest Laboratories (Industry)
29
Study Details
Study Description
Brief Summary
This is a 52-week, multicenter, open label trial of memantine (Namenda) for frontotemporal lobar degeneration (FTLD). The goal is to determine the safety and tolerability of this FDA-approved medication for Alzheimer's Disease in patients with FTLD. Secondary outcome measures include cognitive batteries, rating scales for activities of daily living and neuropsychiatric symptoms. All patients receive the FDA-approved dose of this medication for Alzheimer's disease.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 4 |
Study Design
Study Type:
Interventional
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Study Start Date
:
May 1, 2004
Actual Primary Completion Date
:
Oct 1, 2005
Actual Study Completion Date
:
Oct 1, 2006
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
40 Years
to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Neary et al. Criteria for Frontotemporal Lobar Degeneration
-
Age 40 -80
-
CDR < 3 or MMSE > 15
-
English Speaking
-
Study Partner
Exclusion Criteria:
- Concurrent use of antipsychotic drugs or acetylcholinesterase inhibitors
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- University of California, San Francisco
- Forest Laboratories
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT00187525
Other Study ID Numbers:
- NAM-02A
First Posted:
Sep 16, 2005
Last Update Posted:
Nov 12, 2012
Last Verified:
Nov 1, 2012